Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)

NCT03737370 is registered in ClinicalTrials.gov with Tufts Medical Center as lead sponsor.

NCT NCT03737370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03737370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)
Lead sponsor
Tufts Medical Center
Phase
Phase 1
Overall status
Completed
Start date
January 30, 2018
Completion date
September 30, 2025
Enrollment
43 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castrate resistant prostate cancer